Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: The significance of surgical resection in pancreatic ductal adenocarcinoma (PDAC) with positive peritoneal cytology (PPC) is controversial. This study aimed to evaluate whether preceding chemotherapy could be beneficial for patients with PDAC with PPC.
Methods: Between 2017 and 2019, 34 consecutive PDAC patients diagnosed with PPC without distant metastasis were retrospectively reviewed. Twenty-three patients did not receive neoadjuvant treatment (NAT) and 11 received NAT. All patients received systemic chemotherapy after PPC was confirmed, and they underwent surgical resection if PPC turned negative. The treatment course, ratio of conversion surgery (CS), and prognosis were evaluated. Moreover, the prognosis of PPC patients who underwent up-front surgery without NAT between 2003 and 2016 was analyzed as a comparative cohort.
Results: The median survival time (MST) of the patients without NAT was 31.4 months. CS was performed in 52.2% of the patients. Patients who underwent CS had better prognoses than those who did not undergo CS (p = 0.005). The CS rate was significantly higher in resectable PDAC (78.5%) than in borderline/unresectable PDAC (11.1%) (p = 0.002). The prognosis of patients with resectable PDAC was improved with preceding chemotherapy compared with up-front surgery (MST 13.0 months; p = 0.016). After NAT, the CS rate was low (27.3%), and the MST was only 14.1 months.
Conclusions: As an initial treatment for PDAC patients with PPC, chemotherapy may lead to a favorable prognosis. Especially, resectable PDAC is associated with a greater chance of improved prognosis. Future studies are required to ascertain whether up-front surgery or preceding chemotherapy should be performed for these patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1245/s10434-021-09718-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Accuracy of PET-CT to Assess the Extent of Nodal Disease in Patients with Clinical Stage III Melanoma Following Neoadjuvant Treatment.
Ann Surg Oncol
August 2025
Division of Breast and Melanoma Surgical Oncology, Department of Surgery, Mayo Clinic, Rochester, MN, USA.
Background: Clinical stage III melanoma has a high recurrence rate following surgical dissection. The use of neoadjuvant treatment has been shown to improve long-term outcomes when compared with up-front surgery, with the pathological response being the best predictor. Biomarkers predicting responses and possibly allowing surgical de-escalation are missing.
View Article and Find Full Text PDFToripalimab, bevacizumab, and irinotecan in dMMR/MSI locally advanced colorectal cancer: First-stage results from a phase 1b/2 trial.
Cell Rep Med
August 2025
State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China; Key Laboratory of Carcinogenesis an
This is the first stage of the phase 1b/2 trial evaluating the effectiveness and safety of toripalimab, irinotecan, and bevacizumab in patients with rectal cancer refusing up-front surgery or radiation therapy (rectum cohort) and patients with T4NanyM0 colon cancer (colon cohort) with deficiency of mismatch repair (dMMR) or microsatellite instability (MSI). This trial allows a doctor-patient shared decision-making process to determine whether to omit irinotecan or bevacizumab and the optimal surgery timing. The primary endpoint pathological complete response (pCR) rates in the full analysis set (FAS) and per-protocol set (PPS) are 57.
View Article and Find Full Text PDFCost-Effectiveness of Medial Patellofemoral Ligament Reconstruction for First-Time Patellar Dislocations: A Markov Analysis.
Am J Sports Med
August 2025
Department of Orthopaedic Surgery, Duke University, Durham, North Carolina, USA.
Background: Nonoperative management versus medial patellofemoral ligament reconstruction (MPFLR) for first-time patellar dislocations remains controversial, and it is unclear whether the increased up-front costs from MPFLR are justified.
Purpose: To compare the cost-effectiveness of an initial trial of physical therapy alone to that of early MPFLR to determine the preferred cost-effective treatment strategy for first-time patellar dislocations.
Study Design: Economic and decision analysis; Level of evidence, 3.
Patients With Pancreatic Cancer With Synchronous Liver Oligometastasis Show a Significant Long-Term Survival Benefit From Resection Under Specific Conditions: A Multicenter National Cohort Study.
J Hepatobiliary Pancreat Sci
August 2025
Japan Society of Hepato-Biliary-Pancreatic Surgery, Osaka, Japan.
Background: In this study, we investigated the criteria that predict the long-term survival benefits after surgical resection in patients with pancreatic cancer accompanied by liver oligometastasis.
Methods: In total, 60 patients from 34 high-volume Japanese centers who underwent surgical resection for liver oligometastasis between 2005 and 2020 were included. Univariate and multivariate methods of survival analyses were performed.
The prognostic significance of MMP-8 tissue Immunoexpression in pancreatic ductal adenocarcinoma after neoadjuvant therapy.
Sci Rep
July 2025
Department of Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, 00290, Finland.
Neoadjuvant therapy (NAT) has become increasingly common in pancreatic ductal adenocarcinoma (PDAC). Still, PDAC remains one of the deadliest cancers and clinically useful biomarkers are needed. Matrix metalloproteinase 8 (MMP-8) has previously been identified as a potential biomarker for PDAC patients undergoing up-front surgery.
View Article and Find Full Text PDF